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Background: Smoking is one of the greatest threats to public health worldwide. We integrated phenome-
wide association study (PheWAS) and Mendelian randomization (MR) approaches to explore causal effects of
genetically predicted smoking intensity across the human disease spectrum.
Methods: We conducted PheWAS case-control analyses in 152,483 ever smokers of White-British ancestry,
aged 3973 years. Disease diagnoses were based on hospital inpatient and mortality registrations. Smoking
intensity was instrumented by four genetic variants, and disease risks estimated for one cigarette per day
heavier intakes. Associations passing the FDR threshold (p<00025) were assessed for causality using several
complementary MR approaches.
Findings: Genetically instrumented smoking intensity was associated with 48 conditions, with MR supporting
a possible causal effect for 28 distinct outcomes. Each cigarette smoked per day elevated the odds of respira-
tory diseases by 5% to 33% (nine distinct diseases, including pneumonia, emphysema, obstructive chronic
bronchitis, pleurisy, pulmonary collapse, respiratory failure) and the odds of circulatory disease by 5% to 23%
(seven diseases, including atherosclerosis, myocardial infarction, congestive heart failure, arterial embo-
lisms). Further effects were seen for cancer within the respiratory system and other neoplasms, renal failure,
septicaemia, and retinal disorders. No associations were observed in sensitivity analyses on 185,002 never
smokers.
Interpretation: These genetic data demonstrate the substantial adverse health impacts by smoking intensity
and suggest notable increases in the risks of several diseases. Public health initiatives should highlight the
damage caused by smoking intensity and the potential benefits of reducing or ideally quitting smoking.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
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Over the last fifty years, observational studies have demonstrated
associations between smoking and a wide-range of diseases, particu-
larly lung cancer, respiratory and cardiovascular diseases [1]. How-
ever, most of the evidence has come from association studies which
are susceptible to reverse causality and confounding, and therefore it
is difficult to identify and measure the true causal effects of smoking
or the degree of damage caused by heavier vs. lighter smoking.Mendelian randomisation (MR) provides an alternative method to
determine evidence of causality. MR involves natural randomization
of study participants based on a genetic instrument serving as a
proxy for the exposure of interest, and akin to a randomised con-
trolled trial, it limits the effect of potential confounders and reduces
the likelihood of reverse causation [2]. Several MR studies have been
carried out to determine the influence of smoking behaviours, typi-
cally on a limited range of outcomes. Phenome-wide associations
studies (PheWAS) are increasingly used to evaluate associations
between genetic variants across a wide range of phenotypes [3]. The
approach is similar to a genome-wide association study (GWAS)
which tests associations between a large number of genetic variants
and a single outcome, although in PheWAS we test for associations
Research in context
Evidence before this study
A MEDLINE search using a combination of “smoking”, “phenome-
wide”, and “Mendelian randomization” as key words (including
synonyms and alternative spellings) identified 58 MR studies on
smoking, including three PheWAS. Studies provided convincing
evidence of an increased morbidity and mortality in smokers, par-
ticularly from respiratory and cardiovascular diseases but also
from other conditions. Individual studies suggested protective
effects on outcomes such as Parkinson’s disease, Alzheimer’s Dis-
ease, osteoarthritis, and possibly hayfever. All PheWAS used single
SNPs as instruments.
Added value of this study
We provide evidence for a causal effect of smoking intensity on
a wide range of respiratory, and circulatory diseases, in addition
to neoplasms, mental illness, injury and poisoning, endocrine/
metabolism, sense organ, genitourinary, and infectious dis-
eases. In all cases greater smoking intensity was associated
with harm, with an estimated 5% to 33% increase in the risk of
disease per cigarette smoked.
Implications of all the available evidence
The public health burden by greater smoking intensity is nota-
ble. In addition to smoking intensity, the overall contribution of
smoking on disease outcomes will depend on a range of smok-
ing behaviours, including age of initiation, and duration of
smoking.
2 C. King et al. / EClinicalMedicine 26 (2020) 100488between a single genetic variant (or genetic risk score) and a large
number of disease outcomes. Combining MR with the hypothesis free
PheWAS approach allows us to identify proof of principle for a causal
effect of an exposure across a wide range of outcomes. One smoking
MR-PheWAS has been published in which the authors examined the
effect of smoking instrumented by rs16969968 at the CHRNA3 locus,
in ever and never smokers on 18,000 phenotypes in the UK Biobank.
Using the PHESANT package Millard et al. confirmed the causal
effects of smoking on decreased lung function, and also identified a
novel detrimental effect on facial ageing [4].
In this two-stage hypothesis-free case-control MR-PheWAS we
use information from ever smokers in the UK Biobank to investigate
the effects of genetically predicted smoking intensity on a spectrum
of carefully curated disease outcomes defined based on hospital inpa-
tient registrations and mortality records [5]. Using four variants
determined by a large scale GWAS meta-analysis [6], we instrument
smoking intensity to approximate the effects by each cigarette
smoked per day (CPD), with our multi-SNP approach increasing
power and enabling us to use a number of complementary MR
approaches to validate our findings [7].
2. Methods
2.1. Study design and participants
The UK Biobank contains clinical and genetic data for more than
500,000 participants [8]. Participants were aged 3973 years, at the
time of recruitment between March 13, 2006, and Oct 1, 2010. We
restricted analyses to unrelated (no first-degree, second-degree, or
third-degree relatives) individuals of White-British ancestry, deter-
mined on the basis of self-report and genetic data. Ever smokers
were defined as participants who had smoked at least one cigarettein their life. Never smokers, had never smoked at the time of data col-
lection (see Supplementary Methods for detailed definitions).
Disease outcomes were identified through linkage to hospital epi-
sode statistics and/or the cause of death from the Office of National
Statistics mortality data. We identified International Classification of
Diseases (ICD; ninth and tenth editions) codes in the dataset and con-
verted them into phenotype codes (phecodes), considered to be more
representative of the terminology used in clinical practice [9]. Partici-
pants with a given phecode were defined as cases. A total of 1859
phecodes were listed. We excluded all phecodes with less than 200
cases [10], with 904 phecodes in ever smokers retained for further
analysis (Supplementary Table 1). Controls were selected as partici-
pants without the phecode of interest and without any other phecode
within the same disease category (‘refined controls’). Based on the lit-
erature we identified three phecodes (cancer within the respiratory
system, ischaemic heart disease, and tobacco use disorder) as positive
control outcomes expected to show an association with the genetic
instrument if analyses were unbiased [1].
This research was carried out using UK Biobank data (application
20,175). Explicit informed consent was obtained from all participants
when they enroled in UK Biobank, which itself has approval from the
North West Multicentre Research Ethics Committee and the National
Information Governance Board for Health and Social Care and (11/
NW/0382).
2.2. Genetic information
A GWAS meta-analysis on CPD by the ENGAGE consortium on
31,266 individuals of White European ancestry identified five inde-
pendent SNPs; rs1051730 (CHRNA3), rs6474412 (CHRNB3), rs215605
(PDE1C), rs4105144 (CYP2A6), and rs7260329 (CYP2B6) [6]. Genotyp-
ing in the UK Biobank was carried out using the Axiom platform (see
Supplementary Methods for further details). All five SNPs (or their
proxies) were identified in the UK Biobank data. However, for
rs4105144 data was missing for 37% of participants and no appropri-
ate proxy (r2=08) could be identified. As such this SNP was excluded
and the remaining four SNPs were retrieved from the UK Biobank
GWAS data. Smoking intensity GRS was calculated based on the
weighted sum of the individual risk alleles, with weights based on
the measured effect sizes in the ENGAGE meta-analyses6 (Supple-
mentary Fig. 1).
2.3. Statistical analysis
In the first stage of the analysis, we ran the PheWAS using both
the refined controls, and the default controls (see Supplementary
Methods for definitions). Based on positive control analyses on respi-
ratory cancers, ischaemic heart disease, and tobacco use disorder
(Supplementary Tables 2 and 3) primary analyses were conducted
using refined controls which excluded all individuals with any dis-
ease condition within a category from the control group. The ‘Phe-
WAS’ package in R was used to carry out a logistic regression of each
phecode against the GRS, adjusting for age (years), sex (male versus
female), assessment centre (22 centres), type of genotyping array
(Affymetrix UK BiLEVE Axiom array versus Affymetrix UK Biobank
Axiom array), birth location (deciles of east-coordinate and north
coordinates for place of birth), and 40 genetic principal components
provided by the UK Biobank. For each phecode, its regression analysis
was restricted to individuals with complete information on all varia-
bles in the model. Correction for multiple testing was based on the
false discovery rate (FDR) (p< 0¢0025).
In the second stage we carried out two-sample MR analyses on
those outcomes which passed the FDR threshold, using the TwoSam-
pleMR and MR PRESSO R packages. SNP - exposure effect size esti-
mates were obtained from the primary ENGAGE GWAS data [6], and
SNP - outcome effect size estimates were determined using the UK
C. King et al. / EClinicalMedicine 26 (2020) 100488 3Biobank. Primary analyses were conducted using inverse variance
weighted (IVW) MR complemented by pleiotropy robust approaches
based on different assumptions including MR Egger, weighted
median, weighted mode, and MR PRESSO [7]. MR-Egger was used to
test for directional pleiotropy, but estimates tend to be conservative
and may be biased if the assumption that “the instrument strength is
independent of direct effect” is violated. MR-PRESSO was used to
carry out a global test for pleiotropy by excluding one SNP at a time,
an outlier test to detect potentially pleiotropic outlier variants for
each genetically determined exposure-outcome association, and a
distortion test which determines the extent to which the causal esti-
mates change when the pleiotropic outlier variant is excluded. Using
the TwoSampleMR package, we also generated a scatterplot of SNP
effect on smoking intensity against SNP effect on each outcome, and
carried out leave-one-out sensitivity analysis, to further identify any
potentially pleotropic SNPs. Effect estimates are per a unit increase in
the genetically instrumented number of cigarettes smoked per day.
As part of instrument validation, we checked for evidence of associa-
tion between the smoking intensity GRS and potential confounders
(Supplementary methods, supplementary Table 4). To further explore
whether the smoking intensity GRS was associated with outcomes
other than through the exposure of interest, smoking intensity, we
repeated the PheWAS in never smokers.
Power for the MR was estimated using the method by Burgess
et al [11]. The current study was estimated to have 80% power to
detect a 20% increase in risk per each genetically determined CPD
increase for 92, and a 50% increase for 488 outcomes, using the
refined controls (a=0¢05, r2=0¢03, Supplementary Table 5). Statistical
analyses were carried out in R (version 3.6.1), and Stata (version 16).
2.4. Role of the funding source
The funder of the study had no role in study design, data collec-
tion, data analysis, data interpretation, or writing of the report. CK,
AM, FN, RW, AZ, and EH had full access to all the data in the study. EH
had final responsibility for the decision to submit for publication.
3. Results
We identified 337,484 participants for inclusion, of which 53¢7%
were women (Supplementary Fig. 2. There were 152,482 ever smok-
ers, with a higher prevalence in men compared to women (50¢8% vs.
40¢4%, Table 1). Higher prevalence of smoking was associated with
older age, greater body mass index (BMI), and reduced general healthTable 1
Characteristics of individuals and prevalence of smoki
Characteristic n (%)
Total 337,484
Sex Women 181,236 (53.7)
Men 156,248 (46.3)
Age (in years) 3949 73,849 (21.9)
5059 111,272 (33.0)
6073 152,363 (45.2)
BMI (kg/m2) < 18.5 1673 (0.5)
18.5 - 24.5 109,787 (32.5)
25 - 29.5 143,785 (42.6)
>= 30 81,145 (24.1)
Missing 1094 (0.3)
General health Excellent 56,531 (16.8)
Good 197,169 (58.4)
Fair 68,621 (20.3)
Poor 13,983 (4.2)
Missing 1180 (0.4)
Median and IQR (interquartile range) are considered fo
ated from likelihood ratio test for models adjusted for(Table 1). The GRS explained 3¢94% of the variation in smoking inten-
sity in ever smokers (as defined by CPD). We found no evidence of
association between the smoking intensity GRS and any of the poten-
tial confounders investigated (Supplementary Table 4).
PheWAS analyses using the refined controls identified forty-eight
phecodes which were associated with the GRS in ever smokers after
FDR correction (p< 0¢0025). Signals were observed for disorders of
the respiratory, circulatory, endocrine/metabolic, and genitourinary
systems, and neoplasms, mental disorders, injuries and poisoning,
infectious diseases, and sense organs (Fig. 1). The associations with
the lowest P values were for emphysema (pPheWAS=9¢24 £ 1016),
chronic airway obstruction (pPheWAS=4¢12 £ 1014), pneumonia
(pPheWAS=2¢16 £ 1010), and cancer within the respiratory system
(pPheWAS=6 £ 1010). Greater genetically predicted smoking intensity
was associated with an increased risk of all the outcomes. We found
no associations in never smokers (Supplementary Fig. 3).
We proceeded to carry out two-sample MR analysis of the forty-
eight phecodes, representing thirty-two distinct conditions (full data
in Supplementary Fig. 4 and Supplementary Table 6). IVW MR pro-
vided evidence of a causative effect of genetically instrumented
smoking intensity and increased risk for twenty-eight conditions
(Fig. 2). The lowest P values were observed for pneumonia (OR per
cigarette smoked 1¢12, 95% CI 1¢071¢17), abnormal findings exami-
nation of lungs (OR 1¢19, 95% CI 1¢111.30), cancer within the respi-
ratory system (OR 1¢21, 95% CI 1¢121¢30), emphysema (OR 1¢33,
95% CI 1¢181¢49), and atherosclerosis (OR 1¢23, 95% CI 1¢13  1¢34).
IVW MR, weighted median, weighted mode and MR-PRESSO pro-
vided reasonably consistent associations (Supplementary Fig. 4, Sup-
plementary Table 6). We additionally extrapolated our findings to
reflect differences in smoking 5 or 10 cigarettes per a day for heavier
vs. lighter smokers (Supplementary Table 7).
Emphysema was the only disease outcome associated with genet-
ically instrumented smoking intensity using all five MR methods
(Supplementary Fig. 4, Supplementary Table 6). Twelve disease out-
comes (cancer within the respiratory system, radiotherapy, second-
ary malignant neoplasm, hypoosmolality and/or hyponatremia, other
mental disorder, alcoholism, atherosclerosis, other disorders of arter-
ies and arterioles, pneumonia, obstructive chronic bronchitis, respira-
tory insufficiency, and abnormal findings examination of lungs) were
supported by four of the MR methods. A further thirteen outcomes
(septicaemia; cancer, suspected or other; other retinal disorders;
myocardial infarction; congestive heart failure, non-hypertensive;
peripheral vascular disease, unspecified; empyema and pneumotho-
rax; pleurisy; pleural effusion; pulmonary collapse; interstitial andng.
Ever smokers
Prevalence (n) Median (IQR) P
152,482
40.4 (73,199) 15 (10, 20) <1.0E-300
50.8 (79,283) 20 (15, 25)
38.5 (28,394) 15 (10, 20) 9.54E-148
43.3 (48,166) 20 (10, 20)
49.8 (75,922) 20 (10, 20)
42.5 (711) 15 (10, 20) <1.0E-300
40.3 (44,205) 15 (10, 20)
46.6 (66,915) 20 (10, 20)
49.4 (40,087) 20 (15, 25)
51.6 (564)
36.8 (20,794) 15 (10, 20) <1.0E-300
43.7 (86,145) 16 (10, 20)
53.0 (36,351) 20 (12, 20)
60.9 (8520) 20 (15, 30)
57.0 (672)
r cigarettes smoked per day. P-values are gener-
age, sex, birth location and assessment centres.
Fig. 1. Manhattan plot illustrating the outcomes of the PheWAS analysis of the smoking intensity GRS in ever smokers. The red line indicates the FDR threshold (p<0.0025). Y-axis is
minus log transformed P-value of the association between smoking intensity genetic risk score (GRS) and disease outcomes; the X-axis provides the list of labels of 17 diseases
groups. Arrows pointing up indicate that the smoking intensity GRS is associated with increased odds of disease. Arrows pointing down indicate that the smoking intensity GRS is
associated with decreased odds of disease.
4 C. King et al. / EClinicalMedicine 26 (2020) 100488compensatory emphysema; respiratory failure; other symptoms or
respiratory failure; acute renal failure; and complication of surgical
and medical procedures) were associated with smoking intensity
based on three MR methods. An increased risk of benign neoplasm of
the colon, altered mental status, tobacco use disorder, other chronic
ischaemic heart disease, unspecified, other aneurysm, and other arte-
rial embolism and thrombosis were supported by two analyses meth-
ods. Of all methods, MR-Egger tended to be more conservative, and
only emphysema, obstructive chronic bronchitis, and empyema and
pneumothorax were associated with genetically predicted smoking
intensity based on this analysis method.
No evidence of pleiotropy was observed using MR Egger or leave
one out analysis (Supplementary Fig. 5). MR PRESSO identified
rs7260329 as a potential pleiotropic outlier in analyses on chronic
airway obstruction and other aneurysm. However, MR-PRESSO dis-
tortion test did not identify significant changes in the effect estimates
when this SNP was removed from the analysis.
4. Discussion
Tobacco smoking is the leading preventable cause of death world-
wide, and smokers typically die 10 years earlier than non-smokers.
Despite some decline over the last 1520 years, the global prevalence
of tobacco smoking is still estimated to be about 20% of the popula-
tion aged  15 years [12]. In the U.S. alone 40 million people smoke,
and 16 million people are living with a disease caused by smoking,
costing the economy more than $300 billion per annum through
direct medical costs and loss of productivity [13].
Our hypothesis free MR-PheWAS analysis demonstrated the
extensive consequences of genetically predicted smoking heaviness
on the risk of respiratory diseases, cancers, and cardiovascular dis-
eases. It has also highlighted potential effects on other conditions
such as septicaemia, acute renal failure, electrolyte disturbances, reti-
nal disorders, and complications of surgery or medical procedures.
For some conditions each genetically predicted cigarette per day ele-
vated the odds of disease by over 30%. If taken to reflect larger differ-
ences in smoking, 10 additional cigarettes per a day would predict a
nearly 17-fold increase in the odds of emphysema, 8-fold foratherosclerosis (OR 8¢13), and 6.5-fold for cancer within the respira-
tory system (Supplementary Table 7). This highlights the significant
damage caused by smoking, beyond smoking initiation, and the
potential health benefits which could be gained by reducing the
number of cigarettes smoked, or ideally, complete smoking cessation.
Our analysis has confirmed findings from observational studies
relating to an increased risk of respiratory disease by heavier smok-
ing [14], particularly chronic obstructive pulmonary disease (COPD),
cancer in the respiratory system, and pneumonia. Our results also
provide evidence for an increased risk of many other respiratory con-
ditions. The effects on respiratory health are supported by an earlier
MR PheWAS of smoking intensity which found causal associations
with poor lung function, COPD, and increased cancer of the bronchus
and lung [4]. Furthermore, in a MR study by Vie et al., smoking inten-
sity was associated with increased mortality from respiratory dis-
eases [15].
Greater genetically predicted smoking intensity increased the risk
of many circulatory diseases. Our results show that increased smok-
ing intensity contributes to all forms of ischaemic heart disease
including conditions characterized by both coronary atherosclerosis
(myocardial infarction), and those characterized primarily by coro-
nary vasospasm, including variant and microvascular angina (other
chronic ischaemic heart disease, unspecified), although concurrent
atherosclerosis is not uncommon in angina patients [16]. Other circu-
latory diseases associated with smoking intensity were peripheral
vascular disease, atherosclerosis, arterial embolism, aneurysm, other
disorders of arteries and arterioles, and congestive heart failure.
Associations for smoking intensity and peripheral vascular disease
and aortic aneurysm in the UK Biobank were also previously reported
by Millard et al [4].
Smoking is the primary cause of lung cancer and it has also been
associated with increased risk of many other types of cancer [17]. In
line with earlier MR studies,4,15 we confirmed the strong effect on
cancers of the respiratory tract, but we also report genetic evidence
for causal associations more broadly with radiotherapy, secondary
malignant neoplasms, and other suspected cancer, as well as benign
neoplasm of colon. An important limitation with our study is the abil-
ity to detect only relatively strong associations, and we are unable to
Fig. 2. Inverse-variance weighted mendelian randomisation analyses on the top 32 distinct smoking intensitydisease associations. Number of cases and number of controls are
shown below each disease outcome as (cases, controls). Risk estimates are reported as odds ratios (OR; 95% CI) per one genetically predicted extra cigarette smoked per day. P_Phe-
WAS is P-value from phenome-wide association analysis.
C. King et al. / EClinicalMedicine 26 (2020) 100488 5discount a causal effect on other types of cancer. While we only found
evidence for an effect of smoking intensity on a relatively limited
number of specific cancers, there were a further seven phecodes in
the neoplasms category which showed some evidence of association
(p>0¢0025 to p<0¢05).
In line with our findings, evidence to date has not supported a
strong causal effect of smoking on mental health outcomes. We found
some evidence for an association between greater genetically instru-
mented smoking intensity and selected disorders under the mental
health category including altered mental status, other mental disor-
der, tobacco use disorder, and alcoholism. Altered mental status
seemed to relate to disorientation, while the majority of cases in the‘other mental disorder’ category were individuals with a history of
psychoactive substance abuse, mainly tobacco or alcohol. However,
there is evidence that alcohol and tobacco misuse share some genetic
aetiology, notably in relation to reward pathways [18]. Althoughwe con-
ducted analyses using several complementaryMR approaches, it is possi-
ble that these statistical sensitivity analyses may not have been able to
fully account for related pleiotropic effects, and that this may have par-
ticularly biased associations observed with mental disorders.
In observational studies smoking is associated with an increased
risk of renal injury, changes in renal haemodynamics and vascular
injury [19], and is associated with an increased risk of death from
renal failure [17]. A previous MR study suggested a causal
6 C. King et al. / EClinicalMedicine 26 (2020) 100488relationship between smoking intensity and glomerular hyperfiltra-
tion [20], while our study is the first to report a causative association
between genetically instrumented smoking intensity and acute renal
failure. An increased risk of acute renal failure may be a direct result
of heavy smoking or it could be mediated through other smoking
related outcomes such as cardiovascular disease or infection. In line
with an earlier study [4], we found evidence for a causative effect of
genetically predicted smoking intensity on septicaemia. Further asso-
ciations, not previously reported in smoking MR studies, include
hypoosmolality and/or hyponatremia retinal disorders, and compli-
cations of surgery and medical procedures.
Key strengths of our study include the large sample, which
enabled us to test for causal effects across the spectrum of disease
outcomes, and the analyses with pleiotropy robust methods facili-
tated by use of a multi-SNP instrument for smoking intensity. Fur-
thermore, we implemented a case-control design, only focusing on
carefully curated disease outcomes based on hospital admissions and
mortality registrations and selecting controls as participants free of
related conditions. One earlier MR-PheWAS on smoking intensity
was conducted in the UK Biobank [4], however, this study used a sin-
gle SNP (rs16969968) approach and conducted analyses with the
PHESANT package to identify associations across all available data
fields, including self-reported and other information. Nevertheless,
many of our findings are consistent with this earlier study, and for
example associations with lung cancer, COPD, respiratory failure,
peripheral vascular disease, and septicaemia, were picked up using
both approaches. While our analysis was not designed to detect asso-
ciations with facial ageing which came up in the PHESANT analyses,
we identified several novel associations, including acute renal failure,
retinal disorders, complications of surgery and medical procedures,
in addition to confirming the extensive range of respiratory and car-
diovascular conditions affected by smoking intensity. A particular
strength of our methodology is the use of a conservative control
group, and validation of our outcomes using positive control pheco-
des. Our refined control groups did not include any phecodes relating
to the broad disease category. With reference to hypertension as an
example, our controls excluded anyone with any type of circulatory
disease. We have demonstrated, using positive controls, that this
conservative approach is more robust than using the default control
parameters. No associations were identified in a further sample con-
sisting of 185,002 never smokers, which further substantiates the
plausibility of our findings. As the effects of smoking on disease risk
may take many years to develop, we conducted our analyses in ever
smokers. As a further sensitivity analysis we repeated the PheWAS in
current smokers, and despite the notably smaller sample, results
were similar (data not shown).
Several known smoking related outcomes, including stroke, were
not picked up by our PheWAS, potentially suggesting important limi-
tations with our study. One disadvantage of this study is that our
analyses were only powered to detect relatively strong effects. The
threshold of 200 cases was based on an earlier PheWAS examining
simple SNP-disease risk associations [10]. In the formal Mendelian
randomization setting where statistical power heavily depends on
the strength of the genetic instrument (ie SNP-exposure association),
we were underpowered for many disease outcomes, and hence could
not provide conclusive evidence for many null associations observed
in our PheWAS analysis. We also focused on one smoking related
behaviour, smoking intensity. It is plausible that smoking intensity
may have a more prominent effect on certain disease outcomes,
while other smoking behaviours (for example smoking initiation, age
of smoking initiation, or duration of smoking) may be more impor-
tant for others. For example, genetically instrumented smoking initia-
tion, but not smoking intensity, has previously been associated with
increased risk of ischaemic stroke [21].
An additional methodological limitation to this study was that we
were not able to include CYP2A6 SNP rs4105144 as neither it nor a proxywere available in the dataset. However, we used a multi-SNP approach,
which compared to the earlier single SNP PheWAS instrument [4], pro-
vides increased power and facilitates testing for horizontal pleiotropy.
Even though MR-PRESSO detected some heterogeneity between var-
iants, which may signal presence of pleiotropy, exclusion of the poten-
tially pleiotropic variants did not affect observed associations. Further,
we implemented several modelling strategies (each with different
assumptions on pleiotropic effects) and observed broadly consistent
effect estimates across these approaches. It was also reassuring that we
observed no GRS-disease associations amongst never smokers (i.e. nega-
tive controls), supporting the role of smoking as a mediator of the
observed effects. Population stratificationmay introduce spurious associ-
ations in MR analyses. To minimize this possibility, we restricted our
analysis to white-British ancestry and adjusted all analyses for assess-
ment centre, birth location and top 40 genetic principal components to
account for subtle population structure. We also found no evidence for
association between the GRS and any of the confounders tested. More-
over, given 5% participation rate in the UK Biobank and evidence of a
healthy volunteer effect it is possible that the same factors that contrib-
ute to differences in smoking intensity and the odds of disease affect the
likelihood of taking part in the study, with the possibility of introducing
collider bias. However, collider bias is believed to be less of an issue in
MR analyses than other sources of bias such as pleiotropy or population
stratification [22]. An earlier smoking PheWAS estimated the effects of
related biases under different strengths of simulated confounding and
found that even in the scenario where confounder-smoking status asso-
ciation was very strong (with an odds ratio of 10), there was still no evi-
dence of inflation in false positive rate in the ever smokers [4]. In
addition, we acknowledge that misclassification may have occurred at
both the level of applying ICD codes and also in the automated process
of converting them to phecodes [23,24] Furthermore, MR assumes a lin-
ear effect, which would not be able to precisely capture the detrimental
effects of smoking intensity if the effect is non-linear. Finally, we
acknowledge that this study was carried out in participants of White-
British ancestry and other studies are required to confirm these associa-
tions and their magnitude in other populations.
In the last 1520 years, the proportion of heavy smokers smoking
a pack or more per day has decreased in countries such as the US and
Australia, while there has been an increase in those smoking less
than 10 CPD [25,26] While this reflects progress, our genetic study
suggests that each additional cigarette smoked matters, notably
increasing the risks of cancer, respiratory, circulatory and many other
diseases. Indeed, the risks of many of the leading causes of morbidity
and mortality worldwide are increased by smoking. Public health ini-
tiatives targeting smoking cessation can reduce the burden of these
smoking related diseases, with enormous potential for health and
economic benefits.
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